PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma
dc.contributor.author | Nguyen, Bella Hai | |
dc.contributor.author | Montgomery, Renn | |
dc.contributor.author | Fadia, Mitali | |
dc.contributor.author | Wang, Jiali | |
dc.contributor.author | Ali, Sayed | |
dc.date.accessioned | 2020-12-20T20:58:39Z | |
dc.date.available | 2020-12-20T20:58:39Z | |
dc.date.issued | 2018 | |
dc.date.updated | 2020-11-23T11:50:49Z | |
dc.description.abstract | Aim There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has been studied as a prognostic biomarker in a number of tumors given its central role in antitumoral immune response evasion. Four previously published analyses found PD-L1 positivity to be an adverse survival prognostic factor in MPM. This study aims to further investigate the relationship between PD-L1 expression in mesothelioma tissues and survival outcome. Methods Clinical data of MPM patients from a single institution between 2006 and 2016 were reviewed. Patient's archived tissues were stained with PD-L1 (Clone Ventana SP263). PD-L1 positivity was defined as > 1% membranous staining regardless of intensity. Results Data from fifty eight patients were analyzed. Median age was 73, majority was male (49, 84%) and had ECOG between 0 and 2 (46, 79%). Most common histopathological subtype was epithelioid (42, 72%), 9 (16%) biphasic subtype and 7 (12%) sarcomatoid. Thirty one patients (53%) received best supportive care and twenty seven patients (47%) received chemotherapy or combination treatment. Forty-two patients had positive PD-L1 expression (72.4%). The median survival time for PD-L1 negative group is 15.5 months and 6 months for the positive group. Positive PD-L1 expression is independently correlated with worse prognosis (HR = 2.02; 95% CI, 1.005–4.057; P-value = 0.0484). Conclusions Our analysis found a higher percentage of MPM patients with positive PD-L1 (> 1%) compared to other studies. Highly positive PD-L1 expression was associated with statistically significantly lower median survival time. | |
dc.format.mimetype | application/pdf | en_AU |
dc.identifier.issn | 1743-7555 | |
dc.identifier.uri | http://hdl.handle.net/1885/218664 | |
dc.language.iso | en_AU | en_AU |
dc.publisher | Blackwell Pub. Asia | |
dc.source | Asia-Pacific Journal of Clinical Oncology | |
dc.title | PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma | |
dc.type | Journal article | |
local.bibliographicCitation.issue | 1 | |
local.bibliographicCitation.lastpage | 73 | |
local.bibliographicCitation.startpage | 69 | |
local.contributor.affiliation | Nguyen, Bella Hai, The Canberra Hospital | |
local.contributor.affiliation | Montgomery, Renn, College of Health and Medicine, ANU | |
local.contributor.affiliation | Fadia, Mitali, College of Health and Medicine, ANU | |
local.contributor.affiliation | Wang, Jiali, College of Business and Economics, ANU | |
local.contributor.affiliation | Ali, Sayed, College of Health and Medicine, ANU | |
local.contributor.authoremail | repository.admin@anu.edu.au | |
local.contributor.authoruid | Montgomery, Renn, u4365779 | |
local.contributor.authoruid | Fadia, Mitali, u5039591 | |
local.contributor.authoruid | Wang, Jiali, u5298171 | |
local.contributor.authoruid | Ali, Sayed, u5677745 | |
local.description.notes | Imported from ARIES | |
local.identifier.absfor | 111299 - Oncology and Carcinogenesis not elsewhere classified | |
local.identifier.ariespublication | u4351680xPUB496 | |
local.identifier.citationvolume | 14 | |
local.identifier.doi | 10.1111/ajco.12788 | |
local.identifier.scopusID | 2-s2.0-85032907687 | |
local.identifier.uidSubmittedBy | u4351680 | |
local.type.status | Published Version |